Innovent Announces the First Patient Dosed in the Phase I/II Study of IBI351 (KRAS G12C inhibitor) in Patients with Advanced Malignant Tumors
Excerpt from the Press Release:
SAN FRANCISCO and SUZHOU, China, Sept. 29, 2021 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced a phase I/II clinical study of KRAS G12C inhibitor IBI351 in Chinese patients with solid tumors (ClinicalTrials.gov, NCT05005234) completed dosing of the first subject.
This study is an open-label, multi-center Phase I/II clinical study in Chinese patients with advanced solid tumors (non-small cell lung cancer (NSCLC) and gastrointestinal cancer) harboring KRAS G12C mutation, with the primary objective to assess the safety/tolerability, pharmacokinetics and efficacy of IBI351.
Professor Yilong Wu, principal investigator of the study, tenured director of Guangdong Provincial People’s Hospital and honorary director of Guangdong Lung Cancer Institute, stated: “KRAS is the most common RAS protein subtype, with a high mutation rate in non-small cell lung cancer, pancreatic cancer, colorectal cancer and other cancer cells. Preclinical data showed that IBI351 is sufficiently differentiated from competitors already or about to enter the clinic, and we look forward to positive results in the safety/tolerability and efficacy data of IBI351. We will also continue to explore the application of precision therapy and potential combination therapy to benefit more cancer patients with KRAS G12C mutations.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary Data Management
Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?